Royalty Pharma plc financials

  1. Home
  2. Financials
  3. RPRX
RPRX CIK 0001802768

Source: EDGAR filings · Built 2026-06-02T03:58:10Z

Key metrics by reporting period

Up to six most-recent periods side-by-side. Rows are the curated key lines — revenue, margins, cash, debt, equity, cash-flow totals, plus the derived and valuation metrics we compute on top. For every tag a filer reported in one period, use the single-filing drilldown below.

Derived Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
EBITDA 1.56B 1.29B 1.49B — — —
Working Capital 891.88M 548.52M 1.11B 1.39B 2.71B 2.39B
Net Debt 8.35B 6.68B 5.66B 5.41B 5.56B 4.81B
Operating Margin 65.58% 57.10% 63.37% 13.73% 62.49% 75.17%
Net Margin 32.42% 37.95% 48.20% 1.91% 27.07% 45.94%
Return on Equity (ROE) 7.94% 8.31% 11.25% 0.45% 6.05% 9.85%
Return on Assets (ROA) 3.93% 4.71% 6.93% 0.25% 3.54% 6.09%
Current Ratio 2.40× 1.44× 7.90× 2.19× 16.81× 8.76×
Debt-to-Equity 0.92× 0.74× 0.61× 0.75× 0.69× 0.59×
Effective Tax Rate 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Cash Conversion Ratio 3.23× 3.22× 2.63× 50.06× 3.26× 2.09×
Accruals Ratio -0.09× -0.10× -0.11× -0.13× -0.08× -0.07×
SBC % of Revenue 12.19% 0.10% 0.10% 0.10% 0.11% 0.26%

Valuation Metrics

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
P/E Trailing (Diluted) 21.71× 13.36× 11.10× 395.20× 26.75× 37.92×
EV / EBITDA 19.29× 16.90× 15.14× — — —
P/S 9.17× 6.70× 7.19× 7.74× 7.22× 8.85×
P/B 2.25× 1.47× 1.68× 1.82× 1.61× 1.90×

Income Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Revenues 2.38B 2.26B 2.35B 2.24B 2.29B 2.12B
Research and Development Expense 452.00M 2.00M 52.00M 177.11M 200.08M 26.29M
Operating Income (Loss) 1.56B 1.29B 1.49B 307.06M 1.43B 1.60B
Income Tax Expense (Benefit) 0 0 0 0 0 0
Net Income (Loss) Attributable to Parent 770.95M 858.98M 1.13B 42.83M 619.73M 975.04M
Earnings Per Share, Basic $1.79 $1.92 $2.54 $0.10 $1.49 $1.32
Weighted Average Number of Shares Outstanding, Basic 429.80M 448.19M 447.60M 437.96M 414.79M 375.44M
Earnings Per Share, Diluted $1.78 $1.91 $2.53 $0.10 $1.49 $1.32
Weighted Average Number of Shares Outstanding, Diluted 564.46M 594.11M 602.90M 437.97M 414.80M 375.45M

Balance Sheet

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Cash and Cash Equivalents, at Carrying Value 618.70M 929.03M 477.01M 1.71B 1.54B 1.01B
Assets, Current 1.53B 1.80B 1.27B 2.55B 2.88B 2.70B
Assets 19.62B 18.22B 16.38B 16.81B 17.52B 16.02B
Long-term Debt 8.95B 7.61B 6.14B 7.12B 7.10B 5.82B
Liabilities, Current 636.21M 1.25B 161.38M 1.17B 171.25M 307.89M
Long-term Debt, Excluding Current Maturities 8.57B 6.61B 6.14B 6.12B 7.10B 5.82B
Liabilities 9.91B 7.88B 6.30B 7.29B 7.27B 6.12B

Cash Flow Statement

Concept FY 2025FY 2024FY 2023FY 2022FY 2021FY 2020
Net Cash Provided by (Used in) Operating Activities 2.49B 2.77B 2.99B 2.14B 2.02B 2.03B
Net Cash Provided by (Used in) Investing Activities -1.61B -2.68B -2.07B -1.03B -1.87B -2.76B
Payments for Repurchase of Common Stock 1.23B 229.65M 304.76M 0 0 0
Net Cash Provided by (Used in) Financing Activities -1.19B 361.14M -2.15B -944.86M 385.11M 1.49B

Raw XBRL tagging for a single filing

Every us-gaap and custom concept the filer tagged for one fiscal period, grouped by statement. Start here when a number in the trend table above surprises you and you want to see the exact tag behind it. Derived and valuation rows are omitted here because they already appear in the trend table.

Most recent filing shown by default.

Compare filings side-by-side

Diff any two filings with deltas and added / removed tags.

Immaterial rows are USD line items under 1% of the period's revenue — the noise floor below which a single tag rarely moves the investment thesis. Revenue is read from the filer's top-line concept (Revenues / RevenueFromContractWithCustomerExcludingAssessedTax, with a fallback chain). Non-USD rows, rows without a numeric value, and every row on a filing with no identifiable revenue anchor stay visible. Flip the switch off to see every tag the filer reported for the period.

Loading filing details…

Methodology

All facts on this page come straight from SEC EDGAR XBRL company-facts filings (RPRX CIK 0001802768), grouped by financial statement using FASB's base us-gaap presentation taxonomy. Filers may re-parent concepts onto different statements in their own extension taxonomy, so a handful of rows can show up under a different statement than on the actual 10-K / 10-Q; custom concepts and any we couldn't map fall into Other. Hover a cell to see the fully-qualified concept name and the filer's description.

For the full methodology — statement grouping, the Other bucket, derived metrics, and fact tooltips — see the methodology reference for the statement grouping, the "Other" bucket, derived metrics, and fact tooltips.

Related tickers

SLAB

SILICON LABORATORIES INC.

BW

BABCOCK & WILCOX ENTERPRISES, INC

JPM

JPMORGAN CHASE & CO